Person:
Mas Zubiri, Alicia

Profile Picture
First Name
Alicia
Last Name
Mas Zubiri
URI
https://hdl.handle.net/20.500.14352/84522
Affiliation
Universidad Complutense de Madrid
Faculty / Institute
Veterinaria
Department
Sanidad Animal
Area
Identifiers
UCM identifierScopus Author IDDialnet ID

Filters

2017 - 201912020 - 20241
Reset filters

Settings

Author: Orden Gutiérrez, José Antonio × Subject: 636.09 ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Alternative strategy for visceral leishmaniosis control: HisAK70-Salmonella Choleraesuis-pulsed dendritic cells
    (Comparative Immunology, Microbiology and Infectious Diseases, 2017) Carrión Herrero, Francisco Javier; Domínguez Bernal, Gustavo Ramón; Martínez Rodrigo, Abel; Mas Zubiri, Alicia; Blanco Gutiérrez, María Del Mar; Orden Gutiérrez, José Antonio; Fuente López, Ricardo De La
    Here, we describe a novel approach that exploits an attenuated mutant of Salmonella enterica serovar Choleraesuis as carrier to deliver a plasmid encoding protein HisAK70. Subsequently, dendritic cells (DCs) were pulsed with this vaccine vector. The aim of this study was to evaluate the effectiveness of the prepared HisAK70-S. Choleraesuis-pulsed DCs (HisAK70-SAL DCs) against visceral leishmaniosis (VL). In our ex vivo model of infection, the prepared formulations could decrease parasite growth by up to 80% by augmenting the production of IL-12p40 and by reducing arginase activity (ARG). Also, BALB/c mice when immunised with this formulation showed significant reduction in parasite burden in both spleen (20% of reduction) and liver (75% of reduction). The balance of the immune ratios IFN-γ/IL-10, TNF-α/IL-10, and IgG2a/IgG1 reflected the acquisition of an improved resistant phenotype in HisAK70-SAL DCs vaccinated mice compared to control mice. Our results suggest that HisAK70-SAL DCs could be a promising alternative approach for vaccine delivery that has the potential to fight Leishmania infantum (L. infantum) infection.
  • Thumbnail Image
    Item
    Enhancing Control of Leishmania infantum Infection: A Multi-Epitope Nanovaccine for Durable T-Cell Immunity
    (Animals, 2024) Hurtado Morillas, Clara; Martínez Rodrigo, Abel; Orden Gutiérrez, José Antonio; De Urbina Fuentes, Laura; Mas Zubiri, Alicia; Domínguez Bernal, Gustavo Ramón
    Canine leishmaniosis (CanL) is a growing health problem for which vaccination is a crucial tool for the control of disease. The successful development of an effective vaccine against this disease relies on eliciting a robust and enduring T-cell immune response involving the activation of CD4+ Th1 and CD8+ T-cells. This study aimed to evaluate the immunogenicity and prophylactic efficacy of a novel nanovaccine comprising a multi-epitope peptide, known as HisDTC, encapsulated in PLGA nanoparticles against Leishmania infantum infection in the murine model. The encapsulation strategy was designed to enhance antigen loading and sustain release, ensuring prolonged exposure to the immune system. Our results showed that mice immunized with PLGA-encapsulated HisDTC exhibited a significant reduction in the parasite load in the liver and spleen over both short and long-term duration. This reduction was associated with a cellular immune profile marked by elevated levels of pro-inflammatory cytokines, such as IFN-γ, and the generation of memory T cells. In conclusion, the current study establishes that PLGA-encapsulated HisDTC can promote effective and long-lasting T-cell responses against L. infantum in the murine model. These findings underscore the potential utility of multi-epitope vaccines, in conjunction with appropriate delivery systems, as an alternative strategy for CanL control.